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specific measures (AQLQ-Marks; AQLQ-Juniper, LWAQ,
SGRQ) that were sufficiently comprehensive, reliable,
valid and responsive. For pediatric quality of life, the lit-
erature review identified four generic (FSII-R, KINDL,
CHQ-PF50, and How Are You questionnaire) and spe-
cific (Life Activities Questionnaire for Childhood Asthma,
Childhood Asthma Questionnaire, Pediatric Asthma Quality
of Life Questionnaire and About My Asthma) measures.
Generic measures were less sensitive in mild asthmatics.
Additional areas of interest included patient knowledge/
control of asthma, parental burden, symptom severity
and frequency. Study-specific diaries assessed symptoms
although evidence of their validity was seldom provided;
a noteworthy exception was the Asthma Symptoms
Checklist. The impact of nocturnal symptoms on sleep
was rarely measured; only the LWAQ assessed sleep,
which was found to be responsive to clinical changes. No
other asthma-specific, validated, sleep instruments exist
to date. Only five published studies on PS were found
and used study specific non-standardized measures with
no evidence of formal development/validation. CON-
CLUSION: This review suggests the need for additional
work in the assessment of responsiveness of pediatric
questionnaires, further validation of PS and the impact of
nocturnal symptoms on sleep and fatigue. Parental bur-
den and patient knowledge assessments may also aid in
determining mediating factors between disease, treatment
and outcome.
PRS7
AN ECONOMIC IMPACT OF A DUR 
INTERVENTION ON THE PHARMACOLOGICAL 
MANAGEMENT OF ASTHMA IN CHILDREN
Raut MK, Stuart B, Zuckerman IH
University of Maryland, Baltimore, MD, USA
OBJECTIVE: To evaluate the effectiveness of drug utili-
zation review (DUR) letter intervention on reducing the
cost of medications and other asthma-related expendi-
tures under Medicaid. METHODS: Between April and
July 1999, a DUR intervention designed to improve drug
use among asthmatic children, aged 5 to 18 years, en-
rolled in a mid-eastern Medicaid program was imple-
mented. The DUR intervention focused on the overuse of
short-acting 2-agonist metered dose inhalers using crite-
ria derived from NHLBI 1997 guidelines. The interven-
tion, in the form of a letter identifying the patient(s), each
patient’s prescription and medical care utilization profile,
and the DUR criteria was mailed to each of these physi-
cians. Medicaid administrative and prescription claims
data was continuously reviewed on a month-to-month
basis from July 1999 to February 2000. The intervention
group was compared to historical and concurrent com-
parison groups on several outcome variables: expenses
associated with (1) asthma-related hospitalizations, (2)
emergency department visits, and (3) asthma medication
expense. The economic impact of the intervention was
evaluated based on the analysis of differences in cost pat-
terns between the pre and the post intervention periods.
RESULTS: 382 asthmatic children with evidence of a
short-acting 2-agonist inhaler overuse and 564 physi-
cians who had treated these children were identified. A
71% decrease in short-acting 2-agonist inhaler costs was
observed in the post intervention period. A 31% and a
41% decrease in the expenses to Medicaid for leuko-
triene drugs and anti-cholinergic drugs, respectively, after
the letter intervention was recorded. There was no signif-
icant change observed in the number of recipients hospi-
talized. However there was a 24% decrease in the cost of
asthma-related hospitalizations to the State Medicaid. A
54% reduction in the respiratory related ER costs was re-
ported in the post-intervention period. CONCLUSION:
The study showed that the letter intervention was useful
in reducing asthma-related expenses to Medicaid.
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OBJECTIVE: To investigate the costs associated with
treatment of Chronic Obstructive Pulmonary Disease
(COPD) patients in a managed care population. METH-
ODS: Retrospective cohort analysis was performed using
PharMetric’s Integrated Outcomes database. Study pa-
tients were required to have a diagnosis of COPD (ICD-
9-CM  491, 492, 496). Index date was designated as
the date of first COPD diagnosis during 1997–1998.
Study patients were required to be continuously enrolled
for 6 months prior to and 12 months following the index
date. Medication use, comorbid conditions, 6-months
pre-index and 12 month post-index health care charges
were captured. RESULTS: 4,067 patients were included
in the analysis. The mean age of the sample was 59.2
years (  11.6) and 58% were female. The most com-
mon physician specialty providing the initial diagnosis
was general practitioner, accounting for 35% of all study
patients. Pulmonologists diagnosed less than 8% of pa-
tients. The most common respiratory agents were al-
buterol, ipratropium and corticosteroids, each used in
78%, 68% and 68% of COPD patients respectively. In-
creased age was associated with a significantly higher use
of ipratropium and significantly lower use of corticoster-
oids. For the 12 months following the index date, the
mean total charges for all diagnoses were approximately
$13,894 per patient (  30168), with COPD-specific
charges accounting for over 36% of the total. The single
largest cost category was inpatient care, which accounted
for 57% total (all diagnoses) charges and 76% of COPD-
specific charges. CONCLUSION: COPD is associated
with substantial medical costs, with the majority of those
costs occurring in the inpatient setting. Therefore, eco-
nomic savings could be derived from the introduction of
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newer, more effective treatments which minimize exacer-
bations leading to hospitalizations.
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OBJECTIVES: In the Greek National Health System Pri-
mary health care centres (PHCs) staffed with qualified
General Practitioners (GPs) and non-specialized medical
graduates (rural doctors), obliged to serve in those areas
for nine months, provide care to rural populations. How-
ever, quality of patient care has not been adequately as-
sessed. Combining data from a study aiming to assess the
impact of providers’ education on asthma management,
and qualitative observational assessments from the pa-
tient and provider population, we aim to identify quality
issues of asthma management in the rural population of
Greece. METHODS: Eight PHCs were randomly chosen
in Crete Island and 30 doctors were randomly assigned
to intervention (21) and control groups (9). Interventions
included: intensive educational course from local Univer-
sity Respiratory Clinic, distribution of the GINA asthma
guidelines, specific patient follow-up forms. The inter-
vention doctors identified 102 patients with a verified
asthma diagnosis by a specialist. Follow-up visits were
scheduled at 0, 16 and 32 weeks. Assessments included
trigger factors prevalence, symptom based scores, PEF
and FEV1, and QoL (AQLQ). Patient dropout and pro-
viders’ adherence to the study schedule were investigated.
RESULTS: Initial qualified GPs’ knowledge on asthma
management was poor before but improved after the ed-
ucational course. The intervention doctors showed vari-
able adherence to the study schedule. Reasons include the
termination of rural center residence for rural doctors, in-
creased workload and organizational factors for qualified
GPs. Reasons for patients’ non-adherence include termi-
nation of rural doctors’ term, distance from PHC, profes-
sional reasons etc. Poor professional and patient adher-
ence resulted in an increased prevalence of trigger factors,
including smoking, house dust, in house dampness (smell),
and fireplace smoke. CONCLUSIONS: The quality of
asthma management in rural areas seems poor. Guideline
knowledge does not ensure adherence. Organizational,
behavioural and cultural factors should be further studied.
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To examine the age and gender differences in children
and young adults aged 0–25 in the utilization of asthma
medications. METHODS: The Medicines Monitoring Unit
(MEMO) captures all dispensed medication for the Tay-
side area (population 400,000) and carries out demo-
graphic and drug safety studies. This study examined the
dispensing of asthma medications for 1993 to 1995. RE-
SULTS: From the MEMO databases 130,372 subjects
aged 25 or under were identified. Of this group 18.1% of
males and 16.3% of females had received at least one
prescription for asthma medication. Stratifying by age in
four year bands the age group 1–4 years had the highest
proportion of children with an asthma prescription (29.4%
of males and 23.5% of females, P  0.001 chi squared
test). The proportion of males with an asthma prescrip-
tion was consistently higher than females until the age of
19 after which there was a higher proportion of females.
Logistic regression analysis showed that males were more
likely to be dispensed a prescription for asthma medica-
tion than females (odds ratio 1.14, 95% CI 1.11–1.18, P 
0.001). Those aged under 20 were twice as likely to have
a prescription as those aged 20–25 (odds ratio 2.02, 95%
CI 1.95–2.10, P  0.001). After adjusting for age, gender
and an age and gender interaction, males were still more
likely to have a prescription for asthma than females
(odds ratio 1.72, 95% CI 1.59–1.85, P  0.001). DIS-
CUSSION: The results for males may reflect a higher in-
cidence of asthma or a prescribing bias. The higher num-
ber of females prescribed asthma medications after age
19 may reflect better compliance or a greater number of
GP consultations.
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OBJECTIVES: To investigate the change in quality of life
and wellbeing in children with bronchial asthma (BA).
METHODS: For estimation of quality of life we used
“Childhood questionnaires” (1991–1995) by A. West, D.
French, adapted for Russian by V. Petrov and I. Smole-
nov (1996–1998). In child’s municipal asthma-centre
questionnaire was conducted in 264 children with BA
and 55 children without this disease, age from 4 to 16.
RESULTS of questionnaire showed considerable decreas-
ing quality of daily life in children (4–7 years old) mainly
in severe and middle severe asthma (30,1 against 36,1
marks in healthy patient (P  0,01) and 36,75 in patients
with mild asthma). Increasing of distress degree was de-
fined in all age groups. In children 4–7 years old with
mild asthma the distress mark was 11,75; in middle se-
vere, 12,5; in children 8–11 years old, 21,4 and 24,89
marks high distress mark. Analogous increasing distress
marks with worsening asthma was revealed in children
12–16 years old (38,5 marks in mild BA; 45,07 in middle
severe; 49,5 in severe BA). Quality of daily life in children
